Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-05-28
1995-12-12
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546155, 514253, 5142352, 514307, 514261, 514258, 514259, 514248, 514249, 514 63, A61K 3147
Patent
active
054750075
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a substituted or unsubstituted 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oxime or pharmaceutically acceptable salts thereof which have high binding to the glycine receptor.
REFERENCES:
patent: 2726920 (1955-12-01), Federkiel et al.
patent: 4710508 (1987-12-01), Bergmeier et al.
patent: 5179107 (1993-01-01), Afonso et al.
patent: 5182258 (1993-01-01), Chiou
patent: 5190956 (1993-03-01), Afonso et al.
patent: 5198461 (1993-03-01), Watjen et al.
patent: 5234956 (1993-08-01), Lipton
patent: 5252584 (1993-10-01), Carling et al.
patent: 5268378 (1993-12-01), Baker et al.
Fadda et al. Chem. Abstr. vol. 116 Entry 173980m (1991).
Fadda et al., "Synthesis of Certain Sulphonamides and Aminopyranoquinoline Derivatives from 4-Hydroxyquinoline with Biological Interest," Pharmazie 46:743-744 (1991).
Hardman et al., 5- and 7-Substituted 2-Amino-4-hydroxyquinolines, J. Chem. Soc. 120:614-620 (1988).
Dahn et al., Uber die 1,2-Verschiebung der Saureamidgruppe bei der Benzilsaureumalagerung von Chinisatin, Helvetica Chimica Acta 50:1911-1917 (1967).
Ayres & Roach, "Spectrophotometric Determination of Iron(II) with Quinisatin Oxime", Analyt. Chim. Acta. 26:332-339 (1962).
Boast et al., "The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils", Brain Res. 442:345-348 (1988).
Brady et al., "Stereoisomers of N-Allylnormetazocine: Phencyclidine-Like Behavioral Effects in Squirrel Monkeys and Rats", Science 215:178-180 (Jan. 8, 1982).
Dahn & Donzel, "Uber die 1,2-Verschiebung der Saureamidgruppe bei der Benzilsaureumlagerung von Chinisatin", Helv. Chim. Acta 50:1911-1917 (1967).
Dickenson & Aydar, "Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the rat", Neuroscience Lett. 121:263-266 (1991).
Fadda et al., "Synthesis of certain Sulphonamides and Aminopyranoquinoline Derivatives from 4-Hydroxyquinoline with Biological Interest", J. Indian Chem. Soc. 68:393-395 (Jul. 1991).
Haley et al., "Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat", Brain Res. 518:218-226 (1990).
Hardman & Partridge, "5- and 7-Substituted 2-Amino-4-hydroxyquinolines", J. Chem. Soc. 120:614-620 (1958).
Johnson & Ascher, "Glycine potentiates the NMDA response in cultured mouse brain neurons", Nature 325:529-531 (Feb. 5, 1987).
Kemp et al., "7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex", Proc. Natl. Acad. Sci. USA 85:6547-6550 (Sep. 1988).
Koek et al., "MK-801, a Proposed Noncompetitive Antagonist of Excitatory Amino Acid Neurotransmission, Produces Phencyclidine-Like Behavioral Effects in Pigeons, Rats and Rhesus Monkeys", J. Pharmacol. & Exp. Therap. 245:969-974 (1988).
Leeson et al., "Kynurenic Acid Derivatives: Structure-Activity Relationships for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-Methyl-D-aspartate Receptor", J. Med. Chem. 34:1243-1252 (1991).
Masoud et al., "Studies on Osmium-Quinisatine Oxime Reaction", Revue Roum. Chim. 26:961-965 (1981).
Patel & Mehta, "Synthesis of 2,4-Dihydroxyquinolines Using Phosphoric Acid as the Cyclizing Agent", J. Sci. Industr. Res. 19B:436-438 (Nov. 1960).
Prisyazhnyuk et al., "Synthesis and antimicrobial properties of some quinoline derivatives", Chem. Abstr. 101:171042y (1984).
Schoepp et al., "Neuroprotectant effects of LY 274614, a structurally novel systemically active competitive NMDA receptor antagonist", J. Neural. Trans. 85:131-143 (1991).
Skilling et al., "Differential Effects of C- and N-Terminal Substance P Metabolites on the Release of Amino Acid Neurotransmitters from the Spinal Cord: Potential Role in Nociception", J. Neurosci. 10:1309-1318 (Apr. 1990).
Stankevicius et al., "Comparative mass-spectrometric behavior of o-hydroxynitroso derivatives in the quinoline, isoquinoline and coumarin series", Chem. Abstr. 112:138465t (1990).
Stankevicius et al., "Method of Producing cyano carboxylic acid amides from quinone monooxime derivatives", Chem. Abstr. 115:114174h (1991).
Tricklebank et al., "A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencyclidine", Eur. J. Pharmacol. 141:497-501 (1987).
Tricklebank et al., "The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor", Eur. J. Pharmacol. 167:127-135 (1989).
Wheeler & Meinwald, "Formation and Photochemical Wolff Rearrangement of cyclic .alpha.-Diazo Ketones: D-Norandrost-5-EN-3.beta.-OL-16-Carboxylic Acids", Org. Syn. Coll. 6:840-844 (1988).
Willetts & Balster, "The Discriminative Stimulus Effects of N-Methyl-D-Aspartate Antagonists in Phencyclidine-Trained Rats", Neuropharmacol. 27:1249-1256 (1988).
Zukin et al., "Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors", Brain Res. 294:174-177 (1984).
Cai Sui X.
Keana John F. W.
Weber Eckard
Daus Donald G.
State of Oregon acting by and through the Oregon State Board of
The Regents of the University of California
LandOfFree
1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the u does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the u, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the u will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1359993